Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ORXOY Stock Summary
In the News

MODIA™ paper published in the Journal of Medical Internet Research Mental Health
UPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic (MODIA™) for Adjunctive Treatment of Opioid Use Disorder: Development Study," in the Journal of Medical Internet Research (JMIR) Mental Health.

Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
UPPSALA, Sweden, July 16, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully initiated the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124.

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
UPPSALA, Sweden, July 1, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination with sublingual buprenorphine/naloxone, as part of a clinician-supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use...

Orexo calls for redemption of its outstanding bonds and obtains temporary waiver
UPPSALA, Sweden, Feb. 5, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK 500,000,000 senior unsecured callable floating rate bonds 2017/2021 with ISIN SE0010494450 (the "Bonds")...

Orexo has successfully issued senior unsecured callable floating rate bonds
UPPSALA, Sweden, Feb. 4, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the amount of SEK 500 million, under a framework of SEK 1,000 million with final maturity in February...

Orexo contemplates issue of senior unsecured callable floating rate bonds
UPPSALA, Sweden, Feb. 1, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income investor meetings in the Nordics, commencing on 1 February 2021. An issue of SEK denominated senior...

Orexo strengthens IP rights for overdose rescue drug OX124
UPPSALA, Sweden, Jan. 27, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship pharmaceutical pipeline asset OX124, a naloxone rescue medication for the treatment of...
ORXOY Financial details
ORXOY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 22.66 | 24.4 | 19.29 | 16.46 | 18.17 | |
Net income per share | 3.99 | 6.33 | -2.45 | -6.51 | -5.17 | |
Operating cash flow per share | 7 | 8.29 | 0.49 | -6.67 | -4.56 | |
Free cash flow per share | 6.9 | 7.37 | -5.03 | -8.21 | -5.25 | |
Cash per share | 17.07 | 23.59 | 14.69 | 14.69 | 10.24 | |
Book value per share | 13.78 | 20.4 | 16.24 | 10.19 | 5.64 | |
Tangible book value per share | 10.77 | 17.11 | 9.42 | 2.94 | -0.68 | |
Share holders equity per share | 13.78 | 20.4 | 16.24 | 10.19 | 5.64 | |
Interest debt per share | 9.75 | 10.51 | 8.93 | 16.86 | 16.52 | |
Market cap | 1.94B | 2.14B | 1.52B | 1.25B | 620.23M | |
Enterprise value | 1.67B | 1.66B | 1.31B | 1.29B | 1.03B | |
P/E ratio | 14.07 | 9.75 | -18.02 | -5.57 | -3.49 | |
Price to sales ratio | 2.48 | 2.53 | 2.29 | 2.2 | 0.99 | |
POCF ratio | 8.02 | 7.44 | 90.54 | -5.44 | -3.96 | |
PFCF ratio | 8.14 | 8.37 | -8.8 | -4.42 | -3.44 | |
P/B Ratio | 4.07 | 3.02 | 2.72 | 3.56 | 3.2 | |
PTB ratio | 4.07 | 3.02 | 2.72 | 3.56 | 3.2 | |
EV to sales | 2.13 | 1.97 | 1.97 | 2.29 | 1.65 | |
Enterprise value over EBITDA | 12.9 | 5.77 | 77.79 | -9.14 | -13.87 | |
EV to operating cash flow | 6.9 | 5.79 | 77.79 | -5.64 | -6.56 | |
EV to free cash flow | 7.01 | 6.52 | -7.56 | -4.58 | -5.69 | |
Earnings yield | 0.07 | 0.1 | -0.06 | -0.18 | -0.29 | |
Free cash flow yield | 0.12 | 0.12 | -0.11 | -0.23 | -0.29 | |
Debt to equity | 0.67 | 0.49 | 0.52 | 1.57 | 2.78 | |
Debt to assets | 0.25 | 0.23 | 0.24 | 0.43 | 0.49 | |
Net debt to EBITDA | -2.08 | -1.64 | -12.76 | -0.33 | -5.5 | |
Current ratio | 2.19 | 2.65 | 1.38 | 2.28 | 1.91 | |
Interest coverage | 5.81 | 11.86 | -1.36 | -7.98 | -7.71 | |
Income quality | 2.53 | 1.24 | -0.84 | 1.07 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.21 | 0.17 | 0.15 | 0.27 | 0.32 | |
Research and developement to revenue | 0.21 | 0.21 | 0.34 | 0.48 | 0.51 | |
Intangibles to total assets | 0.08 | 0.08 | 0.19 | 0.2 | 0.2 | |
Capex to operating cash flow | -0.01 | -0.11 | -11.29 | 0.23 | 0.15 | |
Capex to revenue | 0 | -0.04 | -0.29 | -0.09 | -0.04 | |
Capex to depreciation | -0.17 | -0.78 | -4.88 | -1 | -0.35 | |
Stock based compensation to revenue | 0 | 0.01 | -0.03 | 0 | 0 | |
Graham number | 35.17 | 53.9 | 29.94 | 38.63 | 25.62 | |
ROIC | 0.18 | 0.2 | -0.05 | -0.24 | -0.29 | |
Return on tangible assets | 0.12 | 0.16 | -0.08 | -0.22 | -0.2 | |
Graham Net | -3.88 | 8.44 | 1.41 | -5.01 | -8.57 | |
Working capital | 576.1M | 760.2M | 230.3M | 485.3M | 349.6M | |
Tangible asset value | 372.2M | 592.4M | 324.2M | 100.8M | -23.5M | |
Net current asset value | 248.9M | 426.5M | 157.2M | -58.6M | -179.6M | |
Invested capital | 0.67 | 0.49 | 0.52 | 1.57 | 2.78 | |
Average receivables | 0 | 136.25M | 245.15M | 243.5M | 289.1M | |
Average payables | 46.6M | 48.55M | 48.2M | 48.1M | 67.9M | |
Average inventory | 211.9M | 152.7M | 120.1M | 100.35M | 83.45M | |
Days sales outstanding | 0 | 117.73 | 119.8 | 173.91 | 180.66 | |
Days payables outstanding | 101.34 | 170.75 | 261.51 | 227.6 | 308.08 | |
Days of inventory on hand | 368.82 | 455.56 | 603.14 | 426.99 | 265.39 | |
Receivables turnover | 0 | 3.1 | 3.05 | 2.1 | 2.02 | |
Payables turnover | 3.6 | 2.14 | 1.4 | 1.6 | 1.18 | |
Inventory turnover | 0.99 | 0.8 | 0.61 | 0.85 | 1.38 | |
ROE | 0.29 | 0.31 | -0.15 | -0.64 | -0.92 | |
Capex per share | -0.1 | -0.92 | -5.51 | -1.54 | -0.7 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 4.3 | 4.68 | 4.54 | 4.62 | 4.58 | |
Net income per share | -1.04 | -0.77 | -2.67 | -1.86 | -0.37 | |
Operating cash flow per share | 0.42 | -1.77 | -1.42 | -1.79 | -0.37 | |
Free cash flow per share | 0.29 | -1.81 | -1.78 | -1.82 | -0.68 | |
Cash per share | 13.61 | 12.92 | 10.24 | 8.12 | 7.3 | |
Book value per share | 8.99 | 8.68 | 5.64 | 3.76 | 3.6 | |
Tangible book value per share | 8.99 | 8.68 | -0.68 | 3.76 | 3.6 | |
Share holders equity per share | 8.99 | 8.68 | 5.64 | 3.76 | 3.6 | |
Interest debt per share | 16.2 | 16.57 | 17.62 | 15.71 | 15.11 | |
Market cap | 776.64M | 803.79M | 620.4M | 608.23M | 284.05M | |
Enterprise value | 1.08B | 1.22B | 1.03B | 996.23M | 550.05M | |
P/E ratio | -5.44 | -7.58 | -1.69 | -2.38 | -5.64 | |
Price to sales ratio | 5.25 | 4.99 | 3.98 | 3.83 | 1.8 | |
POCF ratio | 53.56 | -13.24 | -12.71 | -9.87 | -22.37 | |
PFCF ratio | 77.66 | -12.9 | -10.17 | -9.75 | -12.09 | |
P/B Ratio | 2.51 | 2.69 | 3.2 | 4.71 | 2.29 | |
PTB ratio | 2.51 | 2.69 | 3.2 | 4.71 | 2.29 | |
EV to sales | 7.29 | 7.6 | 6.59 | 6.27 | 3.49 | |
Enterprise value over EBITDA | -33.13 | -37.76 | -87.85 | -24.24 | 100.01 | |
EV to operating cash flow | 74.26 | -20.15 | -21.06 | -16.17 | -43.31 | |
EV to free cash flow | 107.67 | -19.64 | -16.85 | -15.97 | -23.41 | |
Earnings yield | -0.05 | -0.03 | -0.15 | -0.11 | -0.04 | |
Free cash flow yield | 0.01 | -0.08 | -0.1 | -0.1 | -0.08 | |
Debt to equity | 1.76 | 1.82 | 2.78 | 4.11 | 4.18 | |
Debt to assets | 0.43 | 0.45 | 0.49 | 0.56 | 0.56 | |
Net debt to EBITDA | -9.23 | -12.95 | -34.82 | -9.44 | 48.36 | |
Current ratio | 2.05 | 2.21 | 1.91 | 1.93 | 1.87 | |
Interest coverage | -4.04 | -1.82 | -1.54 | -6.45 | -4.64 | |
Income quality | -0.29 | 1.22 | 0.69 | 1.04 | 0.98 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.35 | 0.34 | 0.41 | 0.42 | 0.24 | |
Research and developement to revenue | 0.55 | 0.48 | 0.57 | 0.49 | 0.48 | |
Intangibles to total assets | 0.19 | 0.19 | 0.2 | 0.22 | 0.21 | |
Capex to operating cash flow | -0.31 | 0.03 | 0.25 | 0.01 | 0.85 | |
Capex to revenue | -0.03 | -0.01 | -0.08 | -0.01 | -0.07 | |
Capex to depreciation | -0.26 | -0.09 | -0.68 | -0.04 | -0.58 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 14.49 | 12.27 | 18.42 | 12.54 | 5.44 | |
ROIC | -0.05 | -0.07 | -0.13 | -0.08 | -0.02 | |
Return on tangible assets | -0.03 | -0.03 | -0.1 | -0.09 | -0.02 | |
Graham Net | -13.16 | -12.13 | -8.56 | -14.81 | -15.06 | |
Working capital | 450.9M | 452.4M | 349.6M | 283.6M | 264.7M | |
Tangible asset value | 73.4M | 68.8M | -23.5M | -78.1M | -74M | |
Net current asset value | -80.1M | -77.4M | -179.6M | -230.9M | -234.4M | |
Invested capital | 1.76 | 1.82 | 2.78 | 4.11 | 4.18 | |
Average receivables | 0 | 0 | 154.5M | 154.5M | 0 | |
Average payables | 0 | 0 | 43.3M | 43.3M | 0 | |
Average inventory | 81M | 86.55M | 81.65M | 69.65M | 65.9M | |
Days sales outstanding | 0 | 0 | 178.27 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 300.93 | 0 | 0 | |
Days of inventory on hand | 358.3 | 285.11 | 259.23 | 202.89 | 351.1 | |
Receivables turnover | 0 | 0 | 0.5 | 0 | 0 | |
Payables turnover | 0 | 0 | 0.3 | 0 | 0 | |
Inventory turnover | 0.25 | 0.32 | 0.35 | 0.44 | 0.26 | |
ROE | -0.12 | -0.09 | -0.47 | -0.49 | -0.1 | |
Capex per share | -0.13 | -0.05 | -0.36 | -0.02 | -0.31 |
ORXOY Frequently Asked Questions
What is Orexo AB (publ) stock symbol ?
Orexo AB (publ) is a SE stock and trading under the symbol ORXOY
What is Orexo AB (publ) stock quote today ?
Orexo AB (publ) stock price is $0.76 today.
Is Orexo AB (publ) stock public?
Yes, Orexo AB (publ) is a publicly traded company.